Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Acta Pharmaciae Indonesia : Acta Pharm Indo Jurnal Penelitian Farmasi Indonesia
Rizki Nur Azmi
Faculty of Pharmacy, Universitas Muhammadiyah Kalimantan Timur
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
EVALUASI KETEPATAN PENGOBATAN DISPEPSIA DI PUSKESMAS WILAYAH PESISIR KALIMANTAN TIMUR Erfan Abdissalam; Aliah Ambarwati; Rizki Nur Azmi
Jurnal Penelitian Farmasi Indonesia Vol 15 No 1 (2026): Jurnal Penelitian Farmasi Indonesia (JPFI)
Publisher : Pusat Penelitian dan Pengabdian Masyarakat (P3M) Sekolah Tinggi Ilmu Farmasi Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51887/jpfi.v15i1.2106

Abstract

Dyspepsia is a prevalent digestive disorder marked by symptoms such as epigastric pain, nausea, vomiting, and a feeling of fullness after meals. Inadequate treatment can diminish the effectiveness of care and increase the likelihood of side effects. Consequently, assessing the appropriateness of dyspepsia treatment is essential to ensure the implementation of rational and effective therapy practices. This study aimed to assess the appropriateness of dyspepsia treatment based on five key parameters of treatment rationality: appropriate indication, medication, dosage, administration route, and timing of drug administration at the Muara Jawa Health Center in Kutai Kartanegara Regency. A descriptive observational approach utilizing a retrospective method was employed for this research. Data were extracted from the medical records of outpatients diagnosed with dyspepsia during the period from July to December 2024. A total of 200 samples were collected using purposive sampling techniques. The evaluation of treatments was conducted in accordance with the guidelines from the National Formulary, the Muara Jawa Health Center Formulary, and the National Consensus on Dyspepsia Management established by the Indonesian Gastroenterology Association (PGI). The results of the study indicated that the pharmaceutical treatments administered to dyspepsia patients at the Muara Jawa Health Center included PPI, H2RA, antacids, prokinetics, and sucralfate. Furthermore, the management of dyspepsia at this facility was deemed appropriate based on accuracy indicators, which encompassed correct indication, correct medication, correct dosage, correct administration route, and correct timing. To enhance the rational use of medications in accordance with national guidelines, regular monitoring and education for medical personnel are essential.
Chemotherapy Regimen and Dosing Accuracy in Stage III and Metastatic Colorectal Cancer Patients at an Indonesian Hospital Erfan Abdissalam; Rizki Nur Azmi; Bintang Dwi Putra; Afifah Puspa Anggraeni; Aulia Rahman; Muhammad Fahmi Hidayat Firdaus; Kunstiarini Kunstiarini
Acta Pharmaciae Indonesia : Acta Pharm Indo Vol 13 No 2 (2025): Acta Pharmaciae Indonesia: Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2025.13.2.15713

Abstract

Background: Cancer, including colorectal cancer, poses a significant global health burden and is the third most prevalent malignancy worldwide. Indonesia, with one of the largest populations globally, recorded 35,676 cases of colorectal cancer from 2017 to 2022. Chemotherapy is recommended as a treatment for colorectal cancer in Indonesia's national guidelines. Objective: This study aimed to analyze the chemotherapy regimen and dosing accuracy for stage III and metastatic colorectal cancer. Methods: An observational cross-sectional study was conducted retrospectively among all colorectal cancer chemotherapy visits in a hospital setting from January to June 2024. The chemotherapy profile and dosing accuracy were assessed according to the national guidelines. Results: This study found that FOLFIRI was the most commonly used treatment (71%), followed by FOLFOX (29%). No targeted therapy was used. In stage III, 20% of FOLFOX and 44% of FOLFIRI were administered with dose rounding, while 8% of FOLFOX and 28% of FOLFIRI were administered outside the recommended range. All five cytotoxic drugs were also administered outside the recommended dose rounding. In the metastatic stage, only FOLFOX was given outside the recommended range (11%), specifically 5-FU at 1200mg/m2 IV continuous. Conclusion: The chemotherapy regimens have been in accordance with the national guidelines. The correct dosing was still greater, although some chemotherapy doses were still found outside the recommended dose range.
Co-Authors Afifah Puspa Anggraeni Aliah Ambarwati Aulia Rahman Bintang Dwi Putra Erfan Abdissalam Erfan Abdissalam Kunstiarini Kunstiarini Muhammad Fahmi Hidayat Firdaus